Orbits Oncology’s Post

The American Association for Cancer Research's 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 is approaching, and my colleagues Renee Vaughn and Bill Leone will attend in San Diego with industry peers from around the US. If you are planning an #Oncology #ClinicalTrial and want to know that it is in good hands from start to finish, arrange a meeting with my colleagues. #conference #meeting #AACR2024 #MakeADifference #Pharma #Biotech #CancerResearch #ClinicalResearch

Topics include: Tabloids and Cancer, Momentum in Biotech- Reversion to the Mean, Follow-On Investing and the Q2 2024 Biotech Outlook #theDoctorisIN #wealthmanagement #financialadvisors #pharma

Twenty three companies will share from £12 million in funding that has been awarded to advance innovative cancer projects and will be shared by 16 projects led by small and medium-sized enterprises at various stages right from feasibility through to regulatory approval. They include industry-led research and development projects by Antikor Biopharma Ltd, Cell Guidance Systems, Coding Bio, Epitopea, Grey Wolf Therapeutics, Lentitek, Medannex Ltd, Mestag Therapeutics, Momentous Therapeutics Ltd, Pathios Therapeutics, Prokarium, QV Bioelectronics, Revolver Therapeutics, #Sferola, Theolytics, VacV Biotherapeutics Feasibility project by CREASALLIS, Galytx, Kargenera, New Path Molecular Research, #OligoTune, Proteotype Diagnostics & Xgenera Congratulations to you all and we look forward to hearing more about the results Find out more via UK Research and Innovation https://lnkd.in/eg5RsCu8 #CancerResearch #InnovationInHealthcare #SmallBusinessGrants #MedicalInnovation #HealthTech #ClinicalTrials #BiotechFunding #HealthcareInnovation #SMEFunding #ResearchAndDevelopment

Interesting new publication in #NatureBiotechnology where the #EuropeanInnovationCouncil (EIC) outlines their investment strategy focusing on innovative biomarkers to personalize cancer treatment and DoMore Diagnostics being showcased as one of their main investments. The author describes the #EIC “…as potentially the most effective catalyst of breakthrough science to disruptive innovation, the EIC has the objective of creating an ecosystem that fosters deeptech science-based businesses by harnessing European research and development efforts, unblocking innovative potential in Europe.” #digitalpathology #precisionmedicine #precisiononcology #cancer #aiinhealth #colorectalcancer #coloncancer #personalizedmedicine Link to the article (paid access): https://lnkd.in/dsd5z-6w

Dr. Hon Leong, scientist in the Odette Cancer Research Program at Sunnybrook Research Institute, emphasizes the importance of translating research into clinical practice. Using ideas from his lab, Dr. Leong founded Sunnybrook spin-off company, YEX Inc., a sustainable, ethical and cost-effective alternative to current methods used for growing cells needed to make biologics drugs. His invention has the potential to improve patient outcomes by accelerating the development of life-saving medications and making them more affordable and accessible for patients. Read more about Yex and Dr. Leong’s experience as an inventor in the latest Sunnybrook Inventors blog: https://bit.ly/3Xog69k

We’re looking forward to being in Boston next month for PEGS, one of the most important protein and antibody engineering events of the year. We’ll be sharing a presentation as part of the Emerging Targets for Oncology and Beyond track on Wednesday 5/15 at 10am; come find out "What’s Wrong With This Picture? The Danger of Inadequate Screens in Antibody Discovery." We also want to hear about your upcoming projects, and talk about how we can work together to help you discover more, discover faster, and discover better. Click below and let us know when’s a good time to get together in Boston. https://hubs.li/Q02tCtBQ0 #PEGSBoston #antibodydiscovery #PEGS24

Exploring Strategic Growth: Cizzle Biotechnology's 2023 Annual Report We are excited to share insights from Cizzle Biotechnology Holdings plc's 2023 Annual Report, which highlights a year of strategic partnerships and advancements in lung cancer detection technologies. Dive into the details of their financial performance, strategic licensing initiatives, and the steps they're taking towards minimizing environmental impact. Discover how these initiatives align with our mission to innovate in healthcare and what lies ahead for Cizzle Biotechnology. 🔗 Read the full summary on our blog: https://buff.ly/4f6vShk #CizzleBiotechnology #AnnualReport #LungCancerAwareness #HealthcareInnovation

How does CHARMED from Sygnature Discovery work in action? Using the clinically relevant oncology target SHP2 in the Ras pathway as a model, we showcase our capabilities in degrader synthesis and the development of high-quality in vitro assays for compound profiling. We demonstrate this through a customer project, where potent degraders were swiftly identified.   Learn more from Dr Steve Young (VP of Business Development) and Dr Hiroki Wada (Business Development Manager) at the poster presentation at EFMC-ACSMEDI MedChem Frontiers in Utrecht, April 8-11. Can’t make the event? Download our digital poster: https://lnkd.in/eN3iQ68U #medicinalchemistry #CHARMED #targetedproteindegradation #drugdiscovery

Thoughts on this? >> New cancer biotech emerges from Stanford research, with help of Nobel laureate Carolyn Bertozzi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #pharmaceutical #biotech

We’ve made significant advancements to our OrganoidXplore™ platform 🌟 Expanded Model Library: We now have a total of 64 models in our comprehensive cancer panel, covering 7 indications.  🌐 Enhanced KRAS Mutant Models: We’ve added 7 new KRAS mutant models, bringing the total to 26 KRAS mutant models. This expansion allows for more detailed insights into mutation-driven cancers. 🔍 Flexible Model Selection: Our platform offers flexible model selection, starting from 20 models. This flexibility ensures that you can design your own panel tailored to your specific research needs. OrganoidXplore™ continues to be the first large panel-based organoid screening service, unique to Crown Bioscience. It accelerates drug discovery and development, from lead compound identification to selecting the right models and indications for meaningful results. Join us on this journey to revolutionize drug discovery and development! #DrugDiscovery #CancerResearch #Organoids #KRAS #Biotech #Innovation #CrownBioscience